ClinicalTrials.gg
CompletedNCT01803087ADO pMDIUpdated Jul 31, 2020

Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients

A Phase 2 interventional study of Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1 and CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2). in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in Poland. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2020-07-31.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing beclomethasone in Asthma — none open to participants now, none under way, none of them phase 3. Beclomethasone · Asthma.

Enrollment
21st of 40
60 · median 67
Started
2012
with 2 others
Phase 2
5 of 40
none open now
Registered
22nd of 40
by date
Lead sponsor
12 of 40
Chiesi Farmaceutici S.p.A.

Among the 40 studies testing beclomethasone in Asthma, this one is the 21st largest by enrollment, is one of 3 that started in 2012, is one of 5 in phase 2, and was the 22nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing beclomethasone in Asthma is open now. The open studies under Asthma, anywhere →

About beclomethasone

Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing beclomethasone in Asthma as a file.
02

Study summary

This clinical pharmacology want to investigate the systemic availability of BDP/B17MP (active metabolite of BDP) and formoterol after single oral inhalation of CHF 1535 100/6 pMDI with and without spacer device (AeroChamber Plus™) and in comparison to a free combination of BDP pMDI plus formoterol pMDI licensed products; this will be additionally compared to the systemic exposure in adults without the spacer device.

Read the detailed description

The proposed clinical pharmacology study is aimed to investigate the systemic availability of BDP/B17MP (active metabolite of BDP) and formoterol after single oral inhalation of CHF 1535 100/6 pMDI (to reach a total dose of BDP 400 µg and formoterol 24 µg) with and without spacer device (AeroChamber Plus™) and in comparison to a free combination of BDP pMDI plus formoterol pMDI licensed products (to reach the same total dose of BDP and formoterol) in adolescent asthmatic patients. The systemic exposure to BDP/B17MP and formoterol after inhalation of CHF 1535 pMDI in adolescents will be additionally compared to the systemic exposure in adults without the spacer device.

The chosen doses correspond to the maximum daily dose of the two components administered as fixed combination.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • adolescents
  • adults
04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients will be enrolled if they meet all of the following criteria:

  1. Male and female adolescents, aged ≥ 12 and \< 18 years at the time of Screening Visit or male and female adults, aged ≥ 18 and ≤ 65 years at the time of Screening Visit.
  2. Written obtained by the patient in case of adult patients and by parents/legal representative and by the minor (according to local regulation).
  3. A diagnosis of asthma as defined in the GINA guidelines (updated 2010) 6 months before the screening visit.
  4. Male/female adolescent and adult patients with asthma stable enough, according to GINA guidelines (updated 2010) and based on the Investigator's opinion, to allow a wash out period from inhaled BDP of 2 days before each single day study treatments and any ICS other than BDP of 1 day before each single day study treatments.
  5. Male/female adolescents and adults asthmatic patients already treated with ICS or ICS/long-acting inhaled β2-agonists or using short-acting inhaled β2-agonists as reliever to control asthma symptoms.
  6. Adolescents and adults with a (FEV1) > 70% of predicted values (% pred) after withholding short acting β2-agonist treatment for a minimum of 6 h prior to screening or 24 hours in case of long acting β2-agonist.
  7. Non- or ex-smokers who smoked less than 5 pack-years (e.g. \< 20 cigarettes per day for 5 years) and stopped smoking for at least 1 year.
  8. A cooperative attitude and ability to be trained about the proper use of pMDI with and without a spacer device and compliant to study procedures.
  9. (BMI) ≥18.5 and ≤ 32 kg/m2

Exclusion criteria

  • Exclusion criteria

Patients will not be enrolled if one or more of the following criteria are present:

  1. Pregnant or breast-feeding female patients. Sexually active female not using efficient throughout the entire study period (e.g. oestro-progestatives, condoms, intrauterine devices). A urinary pregnancy test will be performed at screening and treatment visits (mandatory in the adult population and at discretion of the investigator in the adolescent population) in women of ;
  2. Having received an drug within 2 months before the screening visit (Visit 1).
  3. Diagnosis of , in the adult patients, as defined by the current GOLD guidelines (updated 2010).
  4. Known to the active treatments.
  5. Inability to perform the required breathing technique and blood sampling.
  6. Hospitalization due to exacerbation of asthma within 1 month prior to the screening visit.
  7. Lower respiratory tract infection within 1 month prior to screening visit.
  8. Obesity, i.e. > 97% weight percentile by local standards.
  9. Significant medical history of and/or treatments for cardiac, renal, neurological, hepatic, endocrine diseases, that may interfere with patient's safety, compliance, or study evaluations, according to the Investigator's opinion;
  10. History of drug addiction or excessive use of alcohol (weekly intake in excess of 28 units alcohol; one unit being a glass of beer, wine or a measure of spirits), or excessive consumption of xanthine containing substances (daily intake in excess of 5 cups of coffee, tea, cola, etc) or psychological or other emotional problems likely to invalidate , or limit the ability of the subject to comply with the protocol requirements;
  11. Treatment with a xanthine derivative (e.g. theophylline) formulations in the 4 weeks prior to screening;
  12. Blood donation (450 mL or more) (for the adult population) or significant blood loss in the 12 weeks before the screening visit.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    CHF 1535 100/6 pMDI (Foster®) TEST 1

    Adolescents CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI

    Drug: Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1

  • Active comparator
    CHF 1535 100/6 pMDI (Foster®) AeroChamber Plus™ (TEST 2).

    CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ spacer device in adolescents (TEST 2)

    Drug: CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).

  • Active comparator
    (Qvar®: BDP 400 µg)+(Atimos®: formoterol 24 µg)

    BDP 100 µg pMDI, 4 puffs (Qvar®, total dose: BDP 400 µg) + formoterol fumarate 6 µg pMDI, 4 puffs (Atimos®, total dose: formoterol 24 µg)

    Drug: BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF)

  • Active comparator
    CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI

    Adults CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI

    Drug: CHF 1535 100/6 pMDI (Foster®) (CTR)

Interventions

  • DrugTest treatments CHF 1535 100/6 pMDI (Foster®) TEST1
  • DrugCHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).
  • DrugBDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF)

    Drug page: Beclomethasone

    Also known as: Free combination of BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) in adolescents (REF)

  • DrugCHF 1535 100/6 pMDI (Foster®) (CTR)

    Also known as: CHF 1535 100/6 pMDI (Foster®) in adults (CTR)

06

What researchers measure

Primary outcomes

  1. AUC0-t of B17MP CHF 1535 100/6 pMDI with and without spacer vs free combination of BDP pMDI and formoterol pMDI

    In adolescents, the systemic exposure of B17MP as AUC0-t, after inhalation of CHF 1535 100/6 pMDI with and without spacer device (AeroChamber Plus™) vs already licensed free combination of BDP pMDI and formoterol pMDI without spacer.

    Time frame: : pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.

Secondary outcomes

  1. AUC0-t, AUC0-inf, Cmax, tmax and t½ for BDP and formoterol

    In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs a free combination of licensed BDP and Formoterol pMDIs.

    Time frame: : pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.

  2. AUC0-0.5h, AUC0-inf, Cmax, tmax and t½ for B17MP

    In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs a free combination of licensed BDP and Formoterol pMDIs.

    Time frame: : pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.

  3. plasma glucose and plasma potassium AUC0-t; Cmin; Tmin; Cmax; Tmax

    In adolescents, after inhalation of CHF 1535 100/6 pMDI with and without spacer (AeroChamber Plus™)vs fre combination

    Time frame: : pre-dose (within 5 min from dosing), 5 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.

  4. Heart rate as AUC0-8h of CHF 1535 100/6 pMDI

    In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs free combination

    Time frame: pre-dose (within 5 min from dosing), 5 min; 10 min; 15 min; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.

  5. FEV1; time everaged FEV1 value AUC0-8h; peak FEV1

    In adolescents, after inhalation of CHF1535 100/6 pMDI both with and without spacer vs a free combination of licensed BDP and Formoterol pMDIs.

    Time frame: pre-dose; 30 min; 1, 2, 4, 6 and 8 hr after inhalation.

07

Study locations

1 site
  • Uniwersytecki Szpital Kliniczny nr 1
    Lodz, 90153, Poland
08

References and documents

Publications

  • Kuna P, Govoni M, Lucci G, Scuri M, Acerbi D, Stelmach I. Pharmacokinetics and pharmacodynamics of an extrafine fixed pMDI combination of beclometasone dipropionate/formoterol fumarate in adolescent asthma. Br J Clin Pharmacol. 2015 Sep;80(3):569-80. doi: 10.1111/bcp.12640. Epub 2015 Jun 1. PubMed 25808292 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2012
First posted
Mar 4, 2013
Start
Feb 2012
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Last update
Jul 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01803087
Responsible party
Sponsor
First posted
Mar 4, 2013
Start date
Feb 2012
Primary completion
Oct 2012
Completion
Oct 2012
Last update
Jul 31, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beclomethasone

Start the discussion